Vanguard Fiduciary Trust
ANIK icon

Vanguard Fiduciary Trust’s Anika Therapeutics ANIK Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Sell
87,527
-2,847
-3% -$42.2K ﹤0.01% 2917
2026
Q1 		$1.31M Buy
+90,374
New +$1.05M ﹤0.01% 2788

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Vanguard Fiduciary Trust's ANIK Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Anika Therapeutics (ANIK) stake by 3.2% in Q2 2026, selling an estimated $42.2K and leaving 87,527 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2917.

Vanguard Fiduciary Trust first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.31M in Q1 2026. 132 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Vanguard Fiduciary Trust held 87,527 shares of Anika Therapeutics worth $1.28M as of Q2 2026.
  • Vanguard Fiduciary Trust sold 2,847 Anika Therapeutics shares in Q2 2026, an estimated $42.2K.
  • Anika Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2917 holding.
  • Vanguard Fiduciary Trust first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Anika Therapeutics position peaked at $1.31M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.